Closed-Loop Insulin Therapy Improves Glycemic Control in Children Aged <7 Years: A randomized controlled trial

• Autores: Andrew Dauber, Liat Corcia, Jason Safer, Michael S. D. Agus, Sara Einis, Garry M. Steil
• Localización: Diabetes care, ISSN-e 0149-5992, Vol. 36, Nº. 2, 2013, págs. 222-227
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Abstract OBJECTIVE To assess the possibility of improving nocturnal glycemic control as well as meal glycemic response using closed-loop therapy in children aged <7 years.

    RESEARCH DESIGN AND METHODS This was a randomized controlled crossover trial comparing closed-loop with standard open-loop insulin pump therapy performed in an inpatient clinical research center. Ten subjects aged <7 years with type 1 diabetes for >6 months treated with insulin pump therapy were studied. Closed-loop therapy and standard open-loop therapy were compared from 10:00 P.M. to 12:00 P.M. on 2 consecutive days. The primary outcome was plasma glucose time in range (110�200 mg/dL) during the night (10:00 P.M.�8:00 A.M.). Secondary outcomes included peak postprandial glucose levels, incidence of hypoglycemia, degree of hyperglycemia, and prelunch glucose levels.

    RESULTS A trend toward a higher mean nocturnal time within target range was noted for closed- versus open-loop therapy, although not reaching statistical significance (5.3 vs. 3.2 h, P = 0.12). There was no difference in peak postprandial glucose or number of episodes of hypoglycemia. There was significant improvement in time spent >300 mg/dL overnight with closed-loop therapy (0.18 vs. 1.3 h, P = 0.035) and the total area under the curve of glucose >200 mg/dL (P = 0.049). Closed-loop therapy returned prelunch blood glucose closer to target (189 vs. 273 mg/dL on open loop, P = 0.009).

    CONCLUSIONS Closed-loop insulin delivery decreases the severity of overnight hyperglycemia without increasing the incidence of hypoglycemia. The therapy is better able to reestablish target glucose levels in advance of a subsequent meal. Younger children with type 1 diabetes may reap significant benefits from closed-loop therapy.

    Footnotes Clinical trial reg. no. NCT01421225, clinicaltrials.gov.

    This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-1079/-/DC1.